All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Astellas Pharma's zolbetuximab receives Scottish Medicines Consortium approval for CLDN18.2-positive gastric cancer treatment
Antibody, cancer, monoclonal antibody, gastric cancer, CLDN18.2 target, precision medicine - Read more

THE GOOD
Business Development & Partnerships

Syngene International, Bristol Myers Squibb extend research collaboration through 2035 covering discovery to commercialization
Research collaboration, drug discovery, multi-decade alliance, integrated services - Read more

IRLAB Therapeutics, Biomia collaborate on CNS drug discovery using IRLAB's ISP platform technology
Research collaboration, neurological, AI/ML, small molecule, drug discovery - Read more

DEBRA Research, University Medical Center Groningen launch dedicated clinical trial site for epidermolysis bullosa
Research collaboration, rare disease, clinical trials, R&D - Read more

Guardant Health, Merck & Co. collaborate on companion diagnostics for cancer therapies using Guardant Infinity Smart platform
Strategic collaboration, oncology, diagnostics, companion diagnostics, commercialization - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Nxera Pharma reports positive Ph3 results for Quviviq (daridorexant) targeting orexin receptors in insomnia patients
Small molecule, neurological, orexin receptor antagonist, insomnia, daridorexant - Read more

THE GOOD
Fundraises

Cytotheryx raises $60M Series A, developing cell therapy treatments for liver disease
Cell therapy, liver disease, preclinical, platform technology - Read more

THE GOOD
Investments

Sharp Services invests over €20 million ($23.2M) to expand European injectables packaging capacity amid strong market demand
Injectable drug delivery, operational, major transaction, capacity expansion - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Layoffs

Takeda Pharmaceuticals cuts 243 US jobs, mainly neuroscience teams, ahead of Trintellix exclusivity loss
Small molecule, neurological, cost reduction, operational - Read more

THE BAD
Mergers & Acquisitions

Sun Pharma calls rumored $10B Organon acquisition "speculative" amid reported takeover talks
Biosimilars, women's health, strategic, major transaction - Read more

THE UGLY
Regulatory

Valneva withdraws US chikungunya vaccine Ixchiq application following FDA safety scrutiny and clinical hold
Live-attenuated vaccine, infectious disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here